Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phosphoramidon is a small molecule dipeptide inhibitor derived from the bacterium Streptomyces tanashiensis. It acts as a potent and reversible inhibitor of several zinc metallopeptidases including neprilysin (neutral endopeptidase 24.11), neprilysin 2, thermolysin, and endothelin-converting enzyme (ECE-1). By inhibiting these enzymes—especially neprilysin—it prevents the degradation of various bioactive peptides such as bradykinin and enkephalins. Phosphoramidon is widely used as a biochemical tool in research to study peptidase function and peptide metabolism but is not approved for clinical use[1][2][3][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phosphoramidon.